



April 30, 2025

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051

Scrip code: 512529

Symbol: SEQUENT

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to above referred, please be informed that Alivira Animal Health Limited, Ireland, wholly owned subsidiary of the Company ("**AAHL**"), has been allotted 5700 shares of TL 10000 each at par of Provet Veteriner Urunleri Sanayi Ve Ticaret A. S., Turkey ("**Provet**"), a wholly-owned subsidiary of AAHL.

Details as required under Regulation 30 read with Para A(1) of Part A of Schedule III of the Listing Regulations and the SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with the SEBI circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 is enclosed herewith as Annexure -1.

We request you to take the same on records.

Thanks & Regards,

Yours faithfully,

For **Sequent Scientific Limited**

Yoshita Vora

Company Secretary & Compliance Officer

Encl. As above

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in

Annexure-1

Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sr. No.	Particulars	Remark
1.	Name of the Target entity, details in brief such as size, turnover etc.	<p>Provet Veteriner Urunleri Sanayi Ve Ticaret A. S., Turkey (Provet), was incorporated in Turkey on 08.02.1995 and is a wholly owned subsidiary of AAHL, Ireland and therefore a wholly-owned step down subsidiary of the Company.</p> <p>The turnover of Provet for the financial year ended March 31, 2024 was 640,826,385 TRL.</p>
2.	Whether the acquisition of the Target entity falls within the related party Transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p>Provet, being wholly-owned step down subsidiary of the Company, is a related party of the Company.</p> <p>While Provet is a Related Party to the Company, the acquisition does not qualify as Related Party Transaction as per Regulation 2(zc) of the Listing Regulations.</p> <p>Except to the extent of shares held by AAHL in Provet, none of the Company's promoter/ promoter group / group companies have any interest in the said allotment.</p>
3.	Industry to which Target entity being acquired belongs	Pharmaceuticals
4.	Objects and impact of acquisition	The investment is made in subsidiary for meeting operational / working capital requirement
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None
6.	Indicative time period for completion of the acquisition	Completed
7.	Nature of consideration	Cash
8.	Cost of acquisition and/ or the price at which the shares are acquired	Investment of TL 5,70,00,000 (Equivalent to INR 125,400,000) (5700 shares of TL 10000 each on rights basis).
9.	Percentage of shareholding/ control acquired and/ or number of shares acquired	The Company will continue to hold 100% shareholding in Provet through AAHL.
10.	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country	Provet Veteriner Urunleri Sanayi Ve Ticaret A. S., Turkey (Provet), was incorporated in Turkey on 08.02.1995 and is a wholly owned subsidiary of AAHL, Ireland and therefore

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in



	<p>in which the acquired entity has presence and any other significant information (in brief);</p>	<p>a wholly-owned step-down subsidiary of Sequent. The Company has presence in Turkey.</p> <p>Provet is in the business of veterinary products.</p> <p>Last 3 years turnover (Rs. In Crores)</p> <p>FY 2021-22 – 98.41</p> <p>FY 2022-23 – 142.10</p> <p>FY 2023-24 – 103.30</p>
--	--	--

SeQuent Scientific Limited

Registered Office: 3rd Floor, Srivalli's Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

Tel No.: +91 9391139986 / 22-4111 4777 | **CIN:** L99999TS1985PLC196357

Website: <http://www.sequent.in> | **Email Id:** investorrelations@sequent.in